Servier Said to Face EU Drug-Delay Fine With Teva Next Month

Les Laboratoires Servier and Teva Pharmaceutical Industries Ltd., the world’s largest maker of generic drugs, face European Union antitrust fines as soon as next month over agreements that delayed the release of cheaper versions of a Servier hypertension treatment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.